Language
China’s market regulator fines two pharmas, confiscates revenue for monopolizing APIs

News

HomeHome / News / China’s market regulator fines two pharmas, confiscates revenue for monopolizing APIs
search
RECENT NEWS

May 30, 2023

The effect of Alnus incana (L.) Moench extracts in ameliorating iron overload

May 26, 2023

Herbal Extract Shows Promise in Treating Diabetes

Jun 30, 2023

TikTok greens powder trend explained

Jul 02, 2023

Portable Computing Language 4.0 Adds Intel Level Zero API Driver

Jan 09, 2024

Don't miss Nordstrom's secret private label sale on Caslon, Zella and more

SEND YOUR INQUIRY
SUBMIT

Jul 06, 2023

China’s market regulator fines two pharmas, confiscates revenue for monopolizing APIs

Chi­na’s mar­ket reg­u­la­tor, the State Ad­min­is­tra­tion for Mar­ket

Chi­na's mar­ket reg­u­la­tor, the State Ad­min­is­tra­tion for Mar­ket Reg­u­la­tion, an­nounced on Sun­day that it fined and con­fis­cat­ed rev­enue from two phar­ma com­pa­nies for what it called a mo­nop­o­lis­tic deal.

Grand Phar­ma­ceu­ti­cal was fined $19.68 mil­lion (139.3 mil­lion yuan) and the reg­u­la­tor con­fis­cat­ed $21 mil­lion (149 mil­lion yuan) of what it called "il­le­gal rev­enue" for en­ter­ing in­to a mo­nop­oly with Wuhan Heal­care Phar­ma­ceu­ti­cals over two drugs and their ac­tive phar­ma­ceu­ti­cal in­gre­di­ents (APIs): nor­ep­i­neph­rine bitar­trate and ep­i­neph­rine.

Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters